News Releases

Leading New Gene-based Therapies

Enochian Biosciences Announces Scientific Presentation of a Novel Approach to Potentially Cure Hepatitis B Virus


LOS ANGELES, Dec. 10, 2019 (GLOBE NEWSWIRE) — Enochian Biosciences, a company focused on gene-modified cellular therapy in infectious disease and cancer, announces that important scientific findings reveal an innovative approach to potentially treat and cure Hepatitis B.

Hepatitis B virus (HBV) can be found in 2 billion people (one in three), causes disease in 257 million and kills almost 1 million people every year.

Dr. Serhat Gumrukcu, the inventor of products in the Enochian pipeline and Director of the Seraph Research Institute (SRI), presented the data at the HEP DART scientific conference in Kauai, Hawaii. The data were generated through a collaboration between SRI and Dr. Philippe Gallay of the Scripps Institute. Dr. Gallay is a leader in the field of hepatitis.

On November 25, Enochian announced it was expanding its Infectious Disease Pipeline by Entering into an Agreement in Principle to Acquire an Exclusive License for a Novel Hepatitis B Virus Treatment from SRI.

To review the data presented, please visit: www.hepbcure-sri-enochian.com

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” plans,” “expects,” “aims,” “intends” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Enochian’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Enochian undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

Contact: ir@enochianbio.com

Read more

Enochian Biosciences Announces Scientific Presentation of a Novel Approach to Potentially Cure Hepatitis B Virus

December 10, 2019


Enochian Biosciences Expands its Infectious Disease Pipeline by Entering into an Agreement in Principle to Acquire an Exclusive License for a Novel Hepatitis B Virus Treatment

November 25, 2019


Enochian BioSciences Inventor Named to Two Important Scientific Committees

June 3, 2019


Enochian Biosciences Announces Appointment of Dr. Mark Dybul as Executive Vice-Chair

January 7, 2019


Enochian Biosciences Announces Uplisting to NASDAQ Under Symbol “ENOB”

December 5, 2018


Enochian Biosciences Attending 60th ASH on Nov 30-Dec 4 in San Diego, CA

November 27, 2018


Enochian Biosciences to Present at Biotech Showcase 2019

November 23, 2018


Enochian Biosciences Attending Cell & Gene Meeting on the Mesa on October 3-5, 2018 in La Jolla, California.

September 4, 2018


Enochian Biosciences Announces Appointment of Dr. David Hardy to Scientific Advisory Board

July 3, 2018


Dandrit Biotech announces filing of listing application to the Nasdaq capital market

February 23, 2018


Dandrit Biotech announces completion of the acquisition of Enochian

February 20, 2018


Dandrit Biotech announces acquisition of Enochian New York, NY

January 17, 2018